QDENGA Vaccine: India's First Approved Dengue Vaccine

QDENGA Vaccine: India's First Approved Dengue Vaccine

Context

India's Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller General of India (DCGI) have granted marketing authorisation to QDENGA (TAK-003), making it the first dengue vaccine approved in India. Developed by Takeda Pharmaceutical (Japan), the vaccine is expected to become commercially available in India during the first half of 2027.

History of the Issue

Dengue is one of India's fastest-growing vector-borne diseases, with seasonal outbreaks placing a heavy burden on public health systems. India accounts for nearly one-third of the global dengue burden. Earlier efforts focused mainly on mosquito control, surveillance, and early diagnosis under the National Vector Borne Disease Control Programme (NVBDCP). The first licensed dengue vaccine, Dengvaxia, required pre-vaccination screening due to safety concerns in people without prior dengue infection. QDENGA addresses this limitation by being suitable for both seropositive and seronegative individuals, making mass vaccination more feasible.

Salient Points

QDENGA is a live-attenuated tetravalent dengue vaccine developed using recombinant DNA technology in Vero cells. It provides protection against all four dengue virus serotypes (DENV-1 to DENV-4) and is administered as two subcutaneous doses given three months apart. Clinical trials demonstrated a significant reduction in severe dengue and about 90% protection against dengue-related hospitalisation. In India, it has been approved for individuals aged 4 to 60 years. Takeda has partnered with Biological E, Hyderabad, for domestic production of up to 50 million doses annually.

India's Stand

India considers vaccination an important addition to its dengue control strategy. The Government aims to integrate immunisation with existing measures such as vector control, surveillance, public awareness, and early diagnosis while promoting domestic vaccine manufacturing under the Aatmanirbhar Bharat vision.

Current Status

QDENGA has received regulatory approval after scientific evaluation and Phase III clinical trials in India. Commercial rollout is expected in 2027, with large-scale domestic production supporting both national immunisation efforts and India's role as a global vaccine supplier, particularly for developing countries.

Analytical Questions

Q1. Why should dengue vaccination be seen as a complement to mosquito control rather than a replacement?

Answer: Vaccination protects people from severe disease, but it does not eliminate mosquitoes or stop virus transmission completely. Mosquito control, sanitation, surveillance and public awareness remain essential. A combined approach reduces infections, lowers hospitalisation and provides stronger long-term protection against dengue outbreaks.

Q2. Why is the approval of a vaccine effective for both seropositive and seronegative individuals significant for India?

Answer: India has a large and diverse population where many people do not know whether they had dengue before. A vaccine that works safely without prior blood testing makes mass immunisation easier. It reduces costs, speeds up implementation and improves vaccine access, especially in rural areas.

Q3. How can domestic production of QDENGA strengthen India's healthcare and economic interests?

Answer: Manufacturing the vaccine in India improves availability and reduces dependence on imports. It creates skilled jobs, supports the pharmaceutical industry and strengthens supply chains. India can also export vaccines to other dengue-affected countries, enhancing its role in global health and vaccine diplomacy.

Q4. What challenges should policymakers address before introducing dengue vaccination on a large scale?

Answer: Governments must ensure affordable pricing, adequate vaccine supply, strong cold-chain systems and public awareness. They should identify priority groups, monitor vaccine safety and continue disease surveillance. Effective coordination between vaccination programmes and mosquito control measures will be essential for long-term success.

Q5. How does the approval of QDENGA reflect the importance of science-based public health policy?

Answer: The vaccine was approved after scientific evaluation and clinical trials. This shows that public health decisions should rely on evidence rather than assumptions. Evidence-based policies improve public trust, ensure safety and help governments adopt effective solutions to emerging health challenges while using resources wisely.